Affiliation:
1. Department of Radiation Oncology, University Hospital Muenster, 48149 Muenster, Germany
2. Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne, Dusseldorf, University Hospital of Cologne, 50937 Cologne, Germany
Abstract
Purpose: Hodgkin lymphoma is a hematologic malignancy with excellent outcomes even in advanced stages. Consequently, the importance of treatment-associated toxicity increases. However, the exact estimation of individualized rates is difficult due to different disease extents, treatment strategies and techniques. The following analysis aims at a pre-treatment estimation of relevant mediastinal toxicities. Methods: Normal tissue complication probability calculations were used to evaluate the toxicity rates for the heart, lungs and female breast of patients undergoing radiotherapy for early-stage Hodgkin lymphoma. Overall, 45 Patients of the HD16 and HD17 trials by the German Hodgkin study group were included and risks were calculated using the Lyman–Kutcher–Burman model. Results: The median values for pericarditis, pneumonitis and fibrosis of the left or right breast were 0.0%, 0.0%, 0.7% and 0.6% in the HD16 cohort, and 0.0%, 0.1%, 1.1% and 1.0% in the HD17 cohort, respectively. Correspondingly, none of the included patients displayed any of the evaluated toxicities during clinical follow-up. The use of higher doses (30 Gy) in the HD17 cohort led to an increase in toxicity compared to the HD16 cohort (20 Gy). No significant influence of the planning target volume size or the radiation technique could be found in this study. Conclusion: Both the clinically observed and calculated toxicity rates corroborate the overall low-risk profile of radiotherapy for Hodgkin lymphoma. Further treatment individualization will be attempted in the future.
Reference40 articles.
1. Fuchs, M., Borchmann, P., Greil, R., Hitz, F., Naumann, R., Sasse, S., and Engert, A. (2023, August 16). Hodgkin Lymphom—Onkopedia. Available online: https://www.onkopedia.com/de/onkopedia/guidelines/hodgkin-lymphom/@@guideline/html/index.html.
2. Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group;Fuchs;J. Clin. Oncol.,2019
3. PET-Guided Omission of Radiotherapy in Early-Stage Unfavourable Hodgkin Lymphoma (GHSG HD17): A Multicentre, Open-Label, Randomised, Phase 3 Trial;Borchmann;Lancet Oncol.,2021
4. PET-Guided Treatment in Patients with Advanced-Stage Hodgkin’s Lymphoma (HD18): Final Results of an Open-Label, International, Randomised Phase 3 Trial by the German Hodgkin Study Group;Borchmann;Lancet,2017
5. Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients;Schaapveld;J. Natl. Cancer Inst.,2021